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Factor D, also referred to as C3 proactivator convertase, constitutes the activating
enzyme of the C3 convertase of the alternative pathway (2) . As such, it is an essential
component of initiation and amplification of the pathway (3, 4) . The enzyme cleaves
factor B, or C3 proactivator, into the activation fragment Ba (30,000 daltons) and the
active site bearing fragment Bb (62,000 daltons) (5, 6). This reaction proceeds only
when factor B is in Mg"-dependent association with C3b and results in the formation
of C3b,Bb which is endowed with C3 cleaving activity (2, 7) .
Unlike other alternative pathway components, factor D has escaped unequivocal
elucidation as to its mode of action, probably because it is a trace protein in human
serum and its function is mimicked by certain tryptic enzymes which are unrelated to
complement. Uncertainty persists as to whether factor D (a) is absolutely required for
C3/C5 convertase formation, (b) is physically incorporated into this multimolecular
enzyme, and (c) occurs in plasma and serum in zymogen form, in which case the
mode of activation is unknown.
We wish to report that factor D occurs in human plasma and serum only as an
active enzyme and that it is absolutely required for C3/C5 convertase formation
under physiological conditions without becoming a subunit of this complex enzyme.
Thus, factor D, which is responsible for the first enzymatic event of the alternative
pathway, necessitates no activation and is subject to no consumption. Its function
depends entirely upon proper presentation of its substrate. It may be of biomedical
significance that the enzyme that plays an essential role in the initiation and
amplification of the alternative pathway is available in the circulation of the host in
active form only.
Materials and Methods
Materials. The following materials were purchased from the sources indicated: Bolton-
Hunter reagent (1251), Ametsham Corp., Arlington Heights, Ill.; diisopropylfluorophosphate
(DFP),' phenylmethylsulfonylfluoride (PMSF) and crystallized bovine serum albumin from
* Publication 1586. Supported by U. S. Public Health Service grants AI 07007 and HL 16411. Presented
in part at the American Society of Biological Chemists and American Association of Immunologists Joint
Meeting, Atlanta, Georgia, June, 1978 (1).
$ Supported by Fellowship IG58 of the Delegation a la Recherche Scientifique et Technique, France.
§ Cecil H. and Ida M. Green Investigator in Medical Research, Research Institute ofScripps Clinic.
'Abbreviations used in this paper: DFP, diisopropylfluorophosphate; DTT, dithiothreitol; Ea, rabbit
erythrocytes; GPS, guinea pig serum; GVB++, VB++ containing 0.1% gelatin; GVBE, VB containing 0.1%
gelatin and 0.01 M EDTA; NF, nephritic factor; P, properdin; PMSF, phenylmethylsulfonyl fluoride;
RIA, radioimmunoassay; SDS, sodium dodecyl sulfate; TAME, p-tosyl-r-ar¢inine methyl ester HCI; VB,
isotonic veronal-buffered saline, pH 7.4; VB++, VB containing 1.5 X 10-7 M CaCl2 and 5 X 10-° M
MgC12; Z, lysis.
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Calbiochem, San Diego, Calif; bovine trypsin, Worthington Biochemical Corp., Freehold,
NJ. ; ampholinecarrier ampholytes, LKB Instruments, Rockville, Md. ; EGTA,EastmanKodak
Co., Rochester, N. Y.
Buffers.
￿
VB: isotonic veronal-buffered saline, pH 7.4; VB++: VB containing 1.5 X 10-4 M
CaC12 and 5 X 10-4 M MgCl2; GVB++: VB++ containing 0.1% gelatin; GVBE: VB containing
0.1% gelatin and0.01 M EDTA; DGVB++: halfisotonic VB++, pH 7.4, containing 2.5%sucrose
and 0.1% gelatin; Mg-EGTA: 0.1 M MgC12, 0.1 M EGTA adjusted to pH 7.0 and used in
blood at the final concentration of 5 X 10-3 M EGTA; Mg-GVB: VB containing 1.2 X 10-3
M MgCl2 and 0.1% gelatin.
Purified Components.
￿
Highly purified human C3 (8), factor B (5), and properdin (P) (9) were
isolated as described. Factor D was purified according to Medicuset al. (10) with modifications.
Briefly, human serum containing 0.01 M EDTA was subjected to a four-step procedure,
including chromatography on QAE Sephadex A50 (pH 8.5), CM52 (pH 6.0), and Bio-Rex 70
(pH 7.0). Factor D waseluted at 9, 16, 20 mS,respectively, with alinear salt gradient. Further
purification was obtained by gel filtration on Sephadex G75. 1,600 ml of serum yielded 0.5 mg
of factor D. Highly purified human a-thrombin (2,200 U/mg) was kindly provided by Dr. J.
H. Griffin of the Department of Immunopathology, Scripps Clinic and Research Foundation.
Plasminogen was isolated as described (11) and kindly provided by Dr. J. P. Gorski of this
Department. 1 mg of plasminogen was activated by 30,000 U of streptokinase (Hyland
Diagnostics Div., Travenol Laboratories, Inc., Costa Mesa, Calif.) during 30 min at 37°C in
VB.
Preparation ofFactor D Immune Adsorbent.
￿
The IgG fraction (40% ammonium sulfate precipi-
tate) of rabbit anti-factor D antiserum (12) was coupled to cyanogen bromide-activated
Sepharose utilizing the method of March et al. (13).
Preparation of C3b Coupled to Sepharose.
￿
Sepharose 4B gel was coated with human C3b
accordingto Medicus (14) . In brief, cobra venomfactor coupled to cyanogen bromide-activated
Sepharose was incubated in presence of Factors B, D, and Mg++ and then C3 was added after
washing.
Preparation of Sheep Erythrocytes Bearing C3b (EC3b).
￿
EC3bt ., was prepared as described (9).
Additional C3b was then depositedon the cells by means of the nephritic factor stabilized C3
convertase as reported (15) . The number of C3b molecules per cell estimated by using trace
amountsof 126I-C3 varied between 100,000 and 150,000.
Assays for Factor D
HEMOLYTIC ACTIVITY ASSAY.
￿
50 lul of a mixture of P (3 lug/ml), factor B (15 jig/ml), and
EC3b (2 X 108/ml) in GVB++ was added to 5 pl of sample containing factor D activity and
incubated for 5 min at 37°C. The C3/C5 convertase activity was measured by the extent of
hemolysis produced during 10 min incubation at 37°C in 1 ml of guinea pig serum (GPS)
diluted 1:100 in GVBE (GPE-EDTA). Under these conditions, the C3/C5 convertase activity
was directly proportional to factor D concentration between 1 ng and 10 ng/ml.
RADIOIMMUNOASSAY (eIA).
￿
The packed factor D immune adsorbent was suspended in 3 vol
ofGVB++. 160111 ofthesuspension wasaddedto plastictubescontaining 40,u1ofapreincubated
mixture of the unlabeled protein to be tested and 40 ng of 1261 factor D. After 30 min at 37°C
and 1 h at 4°C, theunbound material was removed by three washings in cold GVB++ andthe
radioactivity of the pellet determined. The specific binding (percent) wascalculated according
to the following formula:
radioactivity (cpm) of experimental pellet - radioactivity (cpm) of control pellet
radioactivity (cpm) of input (40 ng'26I factor D) .
The control pellet was prepared from a reaction mixture that contained 1.2 lug of unlabeled
factor D (30-fold excess over the amount of labeled factor D).
Assays for Esterolytic Activity.
￿
The synthetic esters listed in Table I were dissolved at a
concentration of 0.01 M in 5 X 10-2 M Tris buffer, pH 7.4, containing 1 X 10-3 M CaC12
unless otherwise indicated. 2 lug of factor D were incubated with 1 limol of synthetic ester in a
final Vol of 120 ftl for 1 h at 37°C. The amount of hydrolyzed ester was determined by the
colorimetric method of Roberts (16). In addition, theesterase activity of various enzymes and
factor D was quantitated with P-tosyl-L-arginine methyl ester HCl (TAME) using a spectro-
photometric procedure (17) . Therate of increase of adsorbance of 247 nm was proportional to1500
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TABLE I
Synthetic Substrates
L-Lysyl methyl ester
￿
(LME)
N-Acetyl-L-arginine methyl ester HCI
￿
(AAME)
N-a-Acetyl glycyl-L-lysine methyl ester
￿
(AGI,ME)
N-Acetyl-L-tyrosine methyl ester, hemihydrate
￿
(ATME)*
N-a-Benzoyl-L-arginine methyl ester HCI
￿
(BAME)
N-a-Benzoyl-L-lysine methyl ester HCI
￿
(BLME)
p-Tosyl-L-arginine methyl ester HCI
￿
(TAME)
N-a-Tosyl-L-lysine methyl ester HCI
￿
(TLME)
N-a-CBZ-L-lysine methyl ester HCl
￿
(CBZ LME)
N-CBZ-Glycyl-L-tyrosine methyl ester
￿
(CBZ GTME)*
All chemicals were purchased from Cyclochemical Co., Los Angeles, Calif.,
with the exception of TAME which was obtained from Calbiochem.
* Solubilized by addition of 5% ethanol.
enzyme concentration allowing measurement of TAME units (1 ttmol of TAME
hydrolyzed/min) per mg of enzyme.
Assay for Proteolytic Activity.
￿
A mixture of 100 ttg of B chain of oxidized bovine insulin
(Boehringer Mannheim Biochemicals, Indianapolis, Ind.) and 35 ug of factor D (or 1 hg of
trypsin which was used as positive control) in a final vol of 75 td of VB++ was incubated for 2
h at 37 °C. Degradation of B chain ofinsulin was then examined by thin-layer chromatography
on cellulose sheet (no. 13255, Eastman Kodak Co.) in 1-butanol-acetic acid-water (200:30 :75) .
After 7 h, the chromatogram was developed with ninhydrin spray (18) .
Factor DDepletionfrom HumanSerum.
￿
Factor D depleted sera were obtained by three methods:
first, gel filtration on a Sephadex G75 column (1.5 X 30 cm) of 2 ml ofhuman serum containing
0.01 M EDTA. After elution with VBE, the high molecular weight proteins contained in 0.6
column vol were pooled and concentrated to the original serum volume. This procedure was
repeated twice and the serum finally dialyzed against VB. This technique was also used for
GPS and the pool of low molecular weight proteins eluted after 0.6 column vol was used as
source of guinea pig factor D. Second, 10 ml of serum containing 0.01 M EDTA and adjusted
to pH 7 was passed over a Bio-Rex 70 column (1 .5 X 15 cm) equilibrated with VBE, pH 7.
The breakthrough fraction was collected and dialyzed against VB. Third, immune adsorption
was used as published (19).
Electrophoresis.
￿
Electrophoresis in 1 .2% agarose was performed in barbital buffer, pH 8.6,
0.05 mS, 0.01 M EDTA, for 2 h at 4.6 vol/cm. 7% sodium dodecyl sulfate (SDS) polyacrylamide
gel electrophoresis was performed according to the method of Weber et al. (20). Isoelectrofo-
cusing electrophoresis in Pevikon blocks was performed according to Reisfeld et al. (21) with
2% ampholine (pH 5-9) .
Sucrose Density Gradient Ultracentrifugation.
￿
It was performed in 5 ml linear 5-20% sucrose
density gradients in half isotonic VB++ at pH 6.5, 7.3, or 8.3 at 130,000 g for 5.5 h at 4°C in a
Beckman L5-65 ultracentrifuge using an SW 50 L rotor.
Results
Purified Factor D: Correlation of Protein, Hemolytic Activity, and Radioactivity.
￿
Purified
factor D was radiolabeled with 1251 according to Bolton and Hunter (22), because the
techniques using chloramine T (23) or lactoperoxidase (24) did not achieve iodine
incorporation. Iodine uptake was approximately 15% and the specific radioactivity of
factor D was 0.4 ACi/Ag. The position of the radioactivity in SDS polyacrylamide gels
after electrophoresis was identical in presence or absence of dithiothreitol (DTT) and
corresponded to the single protein band observed upon staining with Coomassie Blue
(Fig. 1) . Factor D hemolytic activity and radioactivity were also superimposed and
found in the yl region upon agarose electrophoresis (Fig. 2).PHILIPPE H. LESAVRE AND HANS J . MULLER-EBERHARD
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FIG . 1 .
￿
Isolated factorD: identical distributionoffactorD protein andprotein bound radioactivity
after 7% SDS polyacrylamide gel electrophoresis . Upper panel : gel containing 40 jig of factor D
stained with Coomassie Blue . Lower panel : radioactivity distribution of gel containing 0.5 ,ug 1261
factor D subjected to electrophoresis under identical conditions. Arrows indicate position ofreference
proteins (phosphorylaseA and reduced fibrinogen) contained in a third gel .
FIG. 2 .
￿
Isolated factor D : identical distribution of hemolytic activity (") and radioactivity (O)
after agarose gel electrophoresis atpH 8.6 (lower panel) . For comparison the immunoelectrophoretic
pattern ofwhole human serum is shown as developed in the same gel (upper panel) .
Absolute Factor D Requirement for the Activation of Proenzyme C3/G'5 Conaertase.
￿
To
investigate the possibility that uncleaved factor B bound to EC3b,P has C3/C5
convertase activity, EC3b,P,B was incubated for 5 min at 37°C in absence or in
presence of excess factorD. The two resulting intermediate complexes will be referred
to, res Sctively, as proenzymeC3/C5 convertase (EC3b,P,B) and asC3/C5convertase
(EC3b,P,Bb). We found that the proenzyme bearing cells were lysed in GPS-EDTA,
but to a lesser extent than the cells bearing the activated enzyme. Proenzyme-
dependent lysis was not due to contamination of factor B with factor D since the
proenzyme complex remained fully stable over a 45-min period at 37°C in GVB++
(Fig. 3) . Proenzyme-dependent lysis was due to activation of the enzyme by factor D
supplied by addition ofGPS-EDTA, as evidenced by the fact that factor D-depleted
GPS-EDTA did not cause lysis. The activity of the depleted GPS was restored by
either guinea pig or human factor D (Table II) . The results show that factor D is
absolutely required for activation of the proenzyme and that although Proenzyme
formation is Mg" dependent, its activation by factor D proceeds in presence of
EDTA .
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￿
Stability of proenzyme C3/C5 Cnvertase at 37°C. 2 X 108 EC3b/ml was incubated with
3,ug/ml P, 5 tag/ml (O) or 25 tag/ml (0) factor B. After 5 min at 37°C the cells were washed in
GVB++ and 200 ng/ml factor D was added to the cells prepared with the low amount of factor B.
50-ul samples were then withdrawn at 5-min intervals and added to 1 ml GPS-EDTA. Lysis was
quantitated after 10 min at 37°C.
TABLE 11
Lack ofHemolytic Activity ofProenzyme C3/C5 Convertase in Absence of
Factor D
Reaction mixture contained per ml 2 X 108 EC3b, 10 Rg P, 30 Wg factor B in
GVB++. After 5 min at 37°C the cells were washed in GVB++ and 50-p1
aliquots ofcell suspension were further incubated for 5 min at 37 °C in presence
or absence of factor D (100 ng/ml). Lysis was measured after incubation for 10
min at 37°C in 1 ml of reagent.
Plasma.
￿
Treatment of human plasma prepared from Mg-EGTA blood with 20 mM
DFP2 for 30 min at 37°C completely abolished the alternative pathway-dependent
lysis of rabbit erythrocytes (ER). The activity of the pathway in the treated plasma
was fully restored by addition of physiological amounts of isolated factor D (Fig. 4).
Increasing the concentration of factor D in untreated and DFP-treated plasma to
approximately nine times the physiological value, lysis increased 9-fold, namely from
z = 0.18 to z = 1.6. At approximately 18 tig/ml plasma, factor D was no longer
limiting.
Depletion of factor D from serum by methods based either on molecular size
(Sephadex G75), charge (Bio-Rex 70) or antigenicity (anti-factor D immune absorb-
ent) gave the same results. The data indicate that under physiological conditions no
other protease in serum or plasma is capable of replacing factor D.
Lack ofIncorporation ofFactor D into the Multimolecular Enzymes.
￿
First, no depletion of
factor D in the fluid phase could be detected after incubation with increasing
concentrations of cellular intermediates. A limiting amount of factor D (0.2 ng) was
incubated at 4°C or 37°C in GVB++ or DGVB++ for 10 s or 5 min with 107 to 2 X
2 Treatment for 30 min at 37 °C in VB with 20 mM DFP was required also for complete inactivation of
isolated factor D; 5 mM resulted in only 70% activation.
Reagent
Lysis (z)
EC3b,P,B
(-factor D)
of:
EC3b,P,Bb
(+factor D)
GPS-EDTA 0.28 1
D-depleted GPS-EDTA 0 1
D-depleted GPS-EDTA + DGP 0.30 1
D-depleted GPS-EDTA + DH' 0.17 1PHILIPPE H. LESAVRE AND HANS J. MOLLER-EBERHARD
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FIG. 4.
￿
Absolute requirement of factor D for alternative pathway-dependent lysis of ER in plasma.
25 ,ul ofMg-EGTA plasma (either treated by DFP [01 or nontreated 101) was incubated in presence
of increasing amounts offactor D with 107 ER in a final 15014 vol ofMg-GVB. After 5 min at 37°C,
the lysis was measured by addition of 1 ml VBE.
108 EC3b. EC3b was either used as such or after preincubation with P (10 ltg/ml), P
and factor B (40 lag/ml), or nephritic factor (NF) (5 ,ug/ml) and factor B. Even in
presence of a 1,000-fold molar excess of cell bound factor B over factor D in the fluid
phase, there was no detectable depletion of factor D hemolytic activity. Second, after
incubation of the same cellular intermediates with an excess of radiolabeled factor D,
radioactivity was never found associated with the cell pellets after separation from the
fluid phase by centrifugation through 200-hl cushions of 20% sucrose DGVB++. Nor
was factor D hemolytic activity found associated with the cell pellets after three
washings, transfer, and decay. Third, we studied the elution of 12,51 factor D (0.5 lag)
at 4°C from columns of Sepharose (S)-C3b, S-C3b,P, and S-C3b,P,B . While about 50
,ug of P and 25 lag of factor B were bound, more than 95% of factor D was recovered
in 1.5 column vol. Fourth, the interaction between 12 '1 factor D with either factor B,
C3, or C3b was investigated by sucrose density gradient ultracentrifugation at
conditions described in Materials and Methods. No interaction could be detected with
100 M excess of factor B, C3, or C3b. Neither was it possible to detect incorporation
of radioactive factor D into the NF-dependent fluid phase C3 convertase (20 lag of
NF, 10 Fig of C3, 2 hg of factor B, 50 ng of 1251 factor D).
Serum Concentration of Factor D as Measured by RIA andHemolytic Activity.
￿
Plasma and
serum samples were obtained from eight healthy donors. A portion of each serum
sample was treated with zymosan (5 mg/ml, 30 min, 37°C) which resulted in more
than 90% C3 consumption. The concentration of factor D was determined on all
samples by the two methods. As shown in Table III, all mean values are approximately
2 lag/ml. No statistically significant difference was found between the values for
plasma and serum, and no statistically significant difference was found between the
values obtained by either RIA or hemolytic assay. Further, serum and zymosan-
activated serum had identical factor D concentrations.
Identical Distribution of Factor D Antigen and Hemolytic Activity in Plasma or Serum After
Fractionation by Chromatography or Electrophoresis. After fractionation of fresh serum on
QAE Sephadex-A50, only one symmetrical peak offactor D antigen was detected, the
distribution of which corresponded to that of factor D hemolytic activity (Fig. 5). The
same result was obtained with fresh plasma after isoelectrofocusing electrophoresis in
a Pevikon block (not shown) .1504
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TABLE III
Factor D: Plasma and Serum Concentration Measured by RIA and Hemolytic
Activity
Factor D concentration*
RIA
Plasma
￿
1.9 t 0.7
￿
2.4 ± 0.9
Serum
￿
2.0 t 0.6
￿
2.3 ± 0.9
Zymosan-activated serum
￿
ND
￿
2.3 t 0.9
* Expressed as average of eight donors t SD. The protein concentration of
purified factor D was determined by Folin analysis with bovine serum
albumin as reference protein.
20 30 40 50 60 10
Fraction Number
Hemolytic activ-
ity
lsg/ml t SD
Frc. 5.
￿
Identical distribution of factor D antigen and hemolytic activity in serum after anion
exchange chromatography. 20 ml of fresh serum in EDTA (0.01 M) was dialyzed against Tris buffer,
0.01 M, pH 8.5, adjusted to 4 mS with NaCl. The sample was applied to a 5 X 30 cm column of
QAE Sephadex A50. The column was washed with starting buffer and the material eluted with a
linear salt gradient (600 ml of the starting buffer and 600 ml of this buffer adjusted to 25 MS) . 10
ml fractions were collected and assayed for factor D hemolytic activity (O) and for factor D antigen
(") by RIA (expressed in percent of inhibition of specific binding). Elution volumes of factor B,
PIH, and C3 are indicated by arrows.
Comparison of Factor D with Other Serine Esterases: Lack of Relationship with a-
Thrombin. The specific factor D hemolytic activity expressed in terms of z/Ftg is
shown for different serine esterases, including factor D, in Table IV. a-thrombin had
no detectable hemolytic activity. Streptokinase activated human plasminogen and
bovine trypsin were, respectively, 4,200 and 35 times less active than factor D. For
comparison, the ability of these serine esterases to cleave TAME is shown. Factor D
has no detectable esterolytic activity' and the esterolytic activities of a-thrombin,
plasmin and bovine trypsin are in agreement with those found in the literature (25,
26, 17) . The absence of factor D hemolytic activity from a-thrombin and the absence
of esterolytic activity from factor D demonstrates that these two molecules are
functionally distinct. Further, as shown in Fig. 6, the binding of factor D in the RIA
was inhibited by unlabeled factor D, but not by a-thrombin. This result led to the
conclusion that a-thrombin and factor D do not share antigenic determinants.
3 No esterolytic activity of factor D was found with respect to nine additional synthetic substrates, and
no cleavage of oxidized B chain of bovine insulin was observed (Materials and Methods).PHILIPPE H. LESAVRE AND HANS J. M DLLER-EBERHARD
TABLE IV
Enzymatic Activity ofFactor D and other Serine Esterases
100,
10
Esterolytic activity
￿
Factor D hemolytic ac-
(TAME cleavage)
￿
ttvity (factor B activa-
tion)
ltmol/min/mg z/ltg
Factor D
￿
<0.006
￿
21,000
a-Thrombin
￿
21
￿
<0.01
Plasmin
￿
7
￿
5*
Bovine trypsin
￿
204$
￿
560* $
* Pretreatment of EC3b cells with enzymes in a control experiment did not
result in impairment of bound C36 function.
$ Completely abolished by treatment of enzyme (30 min at 37°C in VB) with
1 mM DFP or 1 mM PMSF.
n Thrombin
factor 0
0 100 200 300
Unlabeled Protein Added Ing)
FIG. 6.
￿
Lack of immunochemical cross reaction between factor D and a-thrombin. A constant
amount of 1261 factor D (40 ng) was mixed with increasing amounts of unlabeled factor D (O or
a-thrombin (") and assayed by RIA (Materials and Methods).
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Discussion
C3 proactivator convertase was postulated to be an enzyme of the C3 activator
system in 1971 (5), described as such in 1972 (2), shown, as factor D, to be required
for formation of cobra factor-dependent C3 convertase in 1973 (27) and obtained in
isolated form in 1974 (10, 28) .
The present study was undertaken to delineate the mechanism of action of factor
D in molecular terms. In view of the outcome of the study, the following observations
reported in the literature require reinterpretation : (a) occurrence in plasma of
zymogen factor D, in addition to the activated enzyme, D (29) ; (b) activation of the
zymogen by properdin or trypsin (30) ; (c) physical incorporation of factor D activity
and antigen into the C3/C5 convertase (31) ; (d) lack of factor D requirement for the
formation of the properdin or nephritic factor dependent C3 convertase (30, 32, 33) ;
(e) expression of esterolytic activity of factor D with respect to synthetic esters (34,
35) ; and (fl existence of an antigenic and functional relationship to a-thrombin (36) .
Our study yielded the following novel results. Human plasma or serum contain
only enzymatically active factor D. This conclusion is based on the following evidence :
the distribution of factor D hemolytic activity paralleled that of factor D antigen
when plasma or serum were subjected to various separation procedures. An antigen-
ically related, inactive proenzyme with charge or size differing from those of active1506
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factor D could not be found. During purification, or upon alternative pathway
activation in serum, an increase in specific factor D activity (hemolytic activity in
z/,ug of factor D protein) was not observed. Isolated factor D and factor D in whole
serum possessed the same specific activity. In addition, there was no consumption of
factor D as a result of alternative pathway activation in serum or upon interaction of
isolated factor D with cell-bound proenzyme C3/C5 convertase. These results indicate
that factor D requires no activation, can recycle and is not inhibited by the various
protease inhibitors of serum . These results also are in accord with the finding that
factor D is not incorporated into the C3/C5 convertase as an essential subunit . In
fact, it was not possible to demonstrate any association of factor D with the complex
enzyme or with its subunits, either by measurement of factor D radioactivity or
hemolytic activity.
Although factor D is not a part of the C3/C5 convertase subunit structure, it is
absolutely necessary for the formation of the enzyme. This absolute requirement is in
agreement with the results reported by others (3, 4, 19, 37) . The proenzyme C3b,P,B
expresses no convertase activity and, unlike the activated enzyme, is completely stable
at 37 °C . Formation of the proenzyme is Mg"-dependent, but its activation by factor
D is not.
To some extent tryptic enzymes can substitute for factor D function. Pronase,
trypsin, and plasmin have been shown to be active in this respect (38-40) . However,
a-thrombin is incapable of mimicking factor D. An antigenic and functional relation-
ship between the two enzymes, proposed by others (36), could not be verified.
Comparing further the functional properties of factor D with those of trypsin, it is
noted that in contradistinction to trypsin, factor D does not act on factor B in absence
of C3b and Mg", has no detectable esterolytic activity toward synthetic substrates,
no proteolytic activity toward the B chain of insulin, and is relatively insensitive to
inactivation by DFP (6, 29) . Complete inactivation of factor D necessitates more than
20 times the DFP concentration needed for trypsin inactivation. However, the specific
hemolytic activity of factor D, measured in terms of C3/C5 convertase activation, is
35 times greater than that of trypsin.
Although some tryptic enzymes exert a factor D-like effect, no other protease in
normal serum or plasma is able to replace factor D. Selective removal of factor D
activity by a variety of methods, including DFP treatment, totally impaired the
alternative pathway. However, pathway activity could be restored in a dose-dependent
fashion upon addition of isolated factor D to the depleted serum. These experiments
also revealed that factor D is present in human serum in limiting concentration.
Factor D became nonlimiting only at nine times physiological serum concentration.
The mechanism of action of factor D may be formulated in terms of the cryptic site
hypothesis. Factor D occurs in fresh plasma not as proenzyme, but in enzymatically
active form. Factor D has no discernible substrate in unactivated plasma and, unlike
most plasma enzymes, it is not controlled by plasma enzyme inhibitors. The substrate
is formed upon activation of the alternative pathway and consists of the C3b-Mg"
factor B complex. It is within this association product that factor B becomes susceptible
to cleavage and activation by factor D. It is unlikely that association with C3b is
necessary to reveal the susceptible bond in factor B because trypsin, which also
activates factor B, can act on it directly, i.e., in absence of C3b and Mg". It is
proposed therefore that C3b induces factor B to fit into the substrate binding site ofPHILIPPE H. LESAVRE AND HANS J. MOLLER-EBERHARD
￿
1507
factor D. This binding site is envisaged to be cryptic because factor D, an active
trypsin-like enzyme, neither reacts with plasma enzyme inhibitors nor with its natural
substrate unless factor B is induced to fit by its helper molecule, C3b.
That factor D is not only essential for amplification ofthe alternative pathway, but
also for its initiation has been established (41) . The question arises therefore how the
initial C3 convertase may be formed in absence of apparent C3b. It is conceivable
that a reversible association product of native C3 and factor B occurs in unactivated
plasma in very low concentration and that this complex constitutes a surrogate
substrate for the always active factor D. The very small numbers of resulting C3b
molecules deposited on the #1H control restricted surface of activator particles (15,
42) could then initiate the chain reaction of factor D catalyzed C3 convertase
formation.
Summary
Factor D (C3 proactivator convertase) of human serum has been shown to be
absolutely necessary for alternative pathway function, for activation of the C3/C5
convertase of that pathway and not to be a subunit of this enzyme. Factor D was
found to be present in human plasma in active form only, at a concentration of 2
[Lg/ml, and not to be controlled by plasma protease inhibitors or by spontaneous
decay. Unlike trypsin, factor D cleaves and activates factor B only when it is in Mg"-
dependent complex with C3b, has no esterolytic activity, and is unable to cleave the
B chain of insulin. The alleged functional and antigenic relationship of factor D to
a-thrombin could not be verified. The results of this study led to the description of
the mechanism of action of factor D in terms of the cryptic site hypothesis.
We wish to thank Ms. Lorraine Wood for skillful technical assistance.
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